[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 490, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith Ph.D.", "age": 62, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1115221, "exercisedValue": 2853049, "unexercisedValue": 32777390}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 665284, "exercisedValue": 1024663, "unexercisedValue": 1206837}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 811075, "exercisedValue": 1681564, "unexercisedValue": 10104314}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 63, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 812175, "exercisedValue": 0, "unexercisedValue": 7521715}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 53, "title": "Executive Vice President of Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 633737, "exercisedValue": 0, "unexercisedValue": 7283126}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 43, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 42.26, "open": 42.8, "dayLow": 41.27, "dayHigh": 42.94, "regularMarketPreviousClose": 42.26, "regularMarketOpen": 42.8, "regularMarketDayLow": 41.27, "regularMarketDayHigh": 42.94, "payoutRatio": 0.0, "beta": 1.452, "forwardPE": -10.207407, "volume": 1030991, "regularMarketVolume": 1030991, "averageVolume": 1541357, "averageVolume10days": 1100620, "averageDailyVolume10Day": 1100620, "bid": 41.31, "ask": 41.38, "bidSize": 4, "askSize": 4, "marketCap": 7639425536, "fiftyTwoWeekLow": 28.95, "fiftyTwoWeekHigh": 62.4, "priceToSalesTrailing12Months": 10295.722, "fiftyDayAverage": 42.9714, "twoHundredDayAverage": 44.5732, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5646176256, "profitMargins": 0.0, "floatShares": 152088834, "sharesOutstanding": 184795008, "sharesShort": 15912962, "sharesShortPriorMonth": 16292256, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0861, "heldPercentInsiders": 0.021189999, "heldPercentInstitutions": 1.07261, "shortRatio": 11.67, "shortPercentOfFloat": 0.0912, "impliedSharesOutstanding": 184795008, "bookValue": 9.337, "priceToBook": 4.4275465, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -567060992, "trailingEps": -3.66, "forwardEps": -4.05, "enterpriseToRevenue": 7609.402, "enterpriseToEbitda": -9.084, "52WeekChange": 0.42098188, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 41.34, "targetHighPrice": 87.0, "targetLowPrice": 60.0, "targetMeanPrice": 73.28571, "targetMedianPrice": 71.5, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 14, "totalCash": 1549480960, "totalCashPerShare": 9.211, "ebitda": -621556992, "totalDebt": 86706000, "quickRatio": 13.977, "currentRatio": 14.244, "totalRevenue": 742000, "debtToEquity": 5.536, "revenuePerShare": 0.005, "returnOnAssets": -0.2856, "returnOnEquity": -0.47180998, "grossProfits": -425398016, "freeCashflow": -306128000, "operatingCashflow": -539708992, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -845.9528, "financialCurrency": "USD", "symbol": "RVMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Revolution Medicines, Inc.", "corporateActions": [], "postMarketTime": 1740172800, "regularMarketTime": 1740171600, "exchange": "NMS", "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "POST", "regularMarketChangePercent": -2.1769953, "regularMarketPrice": 41.34, "shortName": "Revolution Medicines, Inc.", "epsCurrentYear": -3.43324, "priceEpsCurrentYear": -12.041104, "fiftyDayAverageChange": -1.6314011, "fiftyDayAverageChangePercent": -0.03796481, "twoHundredDayAverageChange": -3.2332, "twoHundredDayAverageChangePercent": -0.07253686, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1581604200000, "postMarketChangePercent": 0.0, "postMarketPrice": 41.34, "postMarketChange": 0.0, "regularMarketChange": -0.91999817, "regularMarketDayRange": "41.27 - 42.94", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1541357, "fiftyTwoWeekLowChange": 12.389999, "fiftyTwoWeekLowChangePercent": 0.42797923, "fiftyTwoWeekRange": "28.95 - 62.4", "fiftyTwoWeekHighChange": -21.060001, "fiftyTwoWeekHighChangePercent": -0.3375, "fiftyTwoWeekChangePercent": 42.09819, "earningsTimestamp": 1740603600, "earningsTimestampStart": 1740603600, "earningsTimestampEnd": 1740603600, "earningsCallTimestampStart": 1740605400, "earningsCallTimestampEnd": 1740605400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.66, "epsForward": -4.05, "displayName": "Revolution Medicines", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]